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Abstract 
The present study investigated aspects of sleep quality in ecstasy and cannabis users. Two-
hundred and twenty seven participants (117 ecstasy/polydrug users, 53 cannabis users and 57 
drug naive participants) took part. The participants completed measures of daytime 
sleepiness, and indicators of sleep quality. The results demonstrated that ecstasy/polydrug 
users viewed themselves as being more evening types and having poorer sleep quality than 
cannabis users and drug naive participants. They were also more likely to have missed out on 
a night’s sleep. The reported differences in sleep type may reflect ecstasy-related serotonergic 
dysfunction resulting in problems with shifting circadian rhythms.   
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Introduction 
There is a considerable body of research evidence indicating that ecstasy users are 
subject to a range of sleep-related problems. Current users whose drug use was largely limited 
to ecstasy reported poorer sleep quality and more sleep time compared with nonusers possibly 
due to short-term post intoxication effects.  However, the same study
[1]
 found that abstinent 
ecstasy-only users also suffered from sleep impairment reporting significantly more night-
time awakenings compared to nonusers. As these individuals had been abstinent for at least 
28 days and on average for over 500 days it appears that sleep problems were a longer term 
consequences of taking the drug. Other post intoxication effects include sleeplessness
[2]
 and 
longer term problems including sleep disturbance and sleep deprivation have been reported by 
ecstasy users
[3,4]
. Evidence of sleep disturbance (from the SCL-90) has been found in both 
heavy
[5]
 and light users of ecstasy
[6]
 and problems appear to persist long after the last occasion 
of use
[7]
. Furthermore, a substantial minority (around 40%) of Parrott et al’s[8] ecstasy-using 
sample identified poor sleep when off drug as a consequence of their ecstasy use showing that 
even relatively short periods of abstinence are associated with sleep problems.  
Laboratory studies have also demonstrated a range of sleep problems among ecstasy 
users (see Schierenbeck et al
[5]
 for a review). For example, Allen et al
[9]
 studied the sleep 
patterns of ecstasy users via EEG and found that they exhibited reduced total sleep time and 
more specifically less non-REM sleep. McCann et al
[10]
  found that MDMA users had lasting 
reductions in the serotonin metabolite CSF 5-hydroxyindoleacetic acid (5-HIAA). They also 
exhibited changes in sleep patterns and personality. Animal studies have also demonstrated 
how MDMA gives rise to neurotoxicity and consequent sleep disturbance. For example, the 
administration of MDMA to adult male rhesus monkeys was associated with pronounced 
elevated activity levels three to four days following administration and disruption of the 
sleep-wake cycle
[11]
. Rats were found to exhibit long-term changes in the regulation of 
circadian rhythms, motor activity and sleep generation following the administration of 
MDMA
[12]
.  
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Aside from the effects of MDMA and ecstasy on sleep quality there is also abundant 
evidence that cannabis has been associated with sleep problems in both animal and human 
studies
[5]
. Santucci et al
[13]
 found that the administration of a cannabinoid receptor antagonist 
to rats increased the time spent in wakefulness reducing slow-wave sleep duration and 
delaying REM sleep onset. The authors suggest that the results are consistent with the 
existence of an endogenous cannabinoid system which has a role in regulating the sleep wake 
cycle.  In a human study Tassinari et al
[14]
 found that administration of a single heavy oral 
dose of THC to cannabis naïve participants caused severe intoxication and sleep impairment 
with a decrease in slow wave sleep and the disappearance of REM stages. Nicholson et al
[15]
 
observed that following the night time administration of Δ-9-tetrahydrocannabinol (THC), the 
following day there was a reduction in sleep latency, increased sleepiness, and mood changes. 
It has been demonstrated that sleep problems are common withdrawal symptoms when 
cannabis users attempt to stop using the drug. In a study from Budney et al
[16]
, current users 
experienced sleep difficulties and strange dreams which persisted for at least 45 days after the 
last ingestion of cannabis. Following cessation of cannabis use the same range of symptoms 
including sleep problems and strange dreams were observed by Arendt et al
[17]
 among a group 
of abstinent individuals seeking treatment for cannabis dependence.  
In a previous study
[18]
 we sought to establish whether ecstasy/polydrug users 
experienced more daytime sleepiness compared with non ecstasy users and if so whether this 
was responsible for the range of cognitive deficits previously observed among the ecstasy-
using sample. Few significant differences in day time sleepiness were observed between users 
and nonusers and there was no evidence that the cognitive deficits we observed were 
mediated by group differences in day time sleepiness. Our previous study
[18]
 failed to address 
a number of potentially important issues. First we failed to consider whether there might be 
any differences between the groups in different aspects of perceived sleep quality such as 
morning wakefulness, perceived sleep type (morning or evening type), the prevalence of 
missing a night’s sleep and the number of hours typically slept each night. Second, we did not 
thoroughly consider the extent to which the sleep problems that were identified might have 
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been due to cannabis use rather than ecstasy. In view of the evidence presented above this 
remains a distinct possibility. The present study attempts to address these omissions. It is 
intended to compare drug naïve, cannabis only, and ecstasy/polydrug users on the various 
sleep measures.  
The aim of the present study therefore is to assess sleep quality in ecstasy polydrug 
users and cannabis users. As ecstasy users frequently co administer cannabis, and also in 
much of the ecstasy literature, control participants were cannabis users, this raises questions 
as to whether the deficits that have been observed were due to cannabis or to ecstasy. It is also 
unclear whether different aspects of sleep quality are adversely affected as well as daytime 
sleepiness. The present study sought to investigate these issues by comparing perceptions of 
sleep quality among ecstasy/polydrug users, cannabis users and drug naive individuals.  It was 
predicted that the two drug using groups will report poorer sleep quality and morning 
alertness, greater daytime tiredness and less sleep time. No prediction is made in relation to 
the sleep type measure. 
 
 
 
METHOD 
Participants.   
In total, 227 individuals were included in the study. There were 117 (53 females) 
ecstasy/polydrug users, 53 (36 females) cannabis-only users, and 57 (43 females) nonusers of 
illicit drugs. Participants were initially recruited through direct approach to Liverpool John 
Moores University undergraduate students. Subsequently, word of mouth referral was used 
with most participants being recruited by this means. Most participants were students (81%), 
with a further 8 and 7% respectively in full and part-time employment. Background data for 
the illicit drug using groups are set out in Table 1. Inspection of the Table reveals the extent 
of poly substance use among the ecstasy/polydrug group. It is also worthy of note that 
cannabis use among this group is far more pronounced compared to the cannabis-only group. 
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The average age of the drug naïve group was 20.91 years (s.d. 1.80), years of education was 
15.37 (s.d. 1.96), and the Ravens score 47.61 (s.d. 5.39).  
<<Insert Table 1 about here>> 
Measures 
Drug Use Questionnaire. Patterns of drug use and other relevant lifestyle variables 
were investigated via means of a background questionnaire. The questionnaire gauged the use 
of ecstasy and other drugs. In relation to illicit drugs, participants were asked a range of 
questions including the last time that they had used each drug and the amount consumed in 
the previous 30 days. Participants were also questioned concerning their history of drug use, 
and these data were used by the experimenters to estimate total lifetime use of each drug. 
The sleep type indicator assesses the extent to which individuals view themselves as 
morning types or evening types. Participants read the following statement: “We hear about 
people who ‘feel better in the morning’ or who ‘feel better in the evening’. Which of these 
two types do you think you are?” Participants respond by selecting one of the following 
alternatives scored 1 to 5 respectively: A. definitely a ‘morning’ type; B. more ‘morning’ than 
‘evening’; C. neither one nor the other; D. more ‘evening’ than ‘morning’; E. definitely an 
‘evening’ type. 
 Sleep quality is assessed by the following question: “How well do you normally sleep 
at night?”  Participants respond by selecting one of the following alternatives scored 1 to 4 
respectively: A. very well; B. satisfactorily; C. not very well; D. very badly. 
 Morning tiredness is assessed by the following question: “How refreshed do you 
usually feel in the mornings?” Participants respond by selecting one of the following 
alternatives scored 1 to 4 respectively: A. very alert; B. fairly alert; C. fairly tired; D. very 
tired.   
Miss a night’s sleep. Participants were asked: ‘Do you sometimes miss a night’s sleep 
or have much less sleep than normal?’ A ‘yes’ or ‘no’ response was obtained. 
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Hours sleep per night. Participants were asked: ‘How long do you usually sleep on a 
typical night?’ and responded indicating the number of hours. 
The Epworth Sleepiness Scale (ESS) represents the likelihood of dozing off during 
the day in various situations with scores exceeding 10 indicative of some form of sleep 
disorder
[19]
. The ESS contains eight items, which a participant has to score on a scale of 0 
(would never doze off in this situation) to 3 (high chance of dozing off in this situation). A 
total score over all eight items was used in the present analysis, with higher scores indicative 
of increased subjective daytime sleepiness. 
 The Karolinska Sleepiness Scale (KSS) measures the participant’s state of sleepiness 
at a given moment in time (see, for example, Gillberg et al
[20]). Participants are asked: ‘Use 
the following scale to indicate how sleepy you are feeling at this moment. Write the number 
in the box.’ Nine numerical response alternatives are listed vertically with verbal labels 
assigned to alternate numbers: 1. Extremely Alert; 2 ; 3 Alert; 4 ; 5 Neither Alert Nor Sleepy; 
6 ; 7 Sleepy But Not Fighting Sleep; 8 ; 9 Extremely Sleepy, Fighting Sleep, Effort to Stay 
Awake. The participant selects the number which corresponds to their present state and writes 
it in a box situated at the bottom of the page. Thus responses range from 1 to 9 with higher 
numbers indicative of greater sleepiness. The measure was administered twice, once at the 
beginning of testing and a second time at the end of the session
1
. 
Participants completed a range of other measures the results of which have been 
reported elsewhere
[18]
. They are included in the present paper for completeness. 
 Computation Span. Participants were required to solve a number of arithmetic 
problems (e.g., 4+7 = ?) by circling one of three multiple-choice answers as each 
problem was presented. They were also required to simultaneously remember the 
second digit of each presented problem. At the end of each set of problems the second 
digits had to be recalled in the order in which they were presented. The number of 
arithmetic problems that the participant had to solve, while at the same time 
remembering each second digit, gradually increased as the test proceeded. In order to 
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proceed, the participant was required to be correct in at least two of the three trials at 
the current level. Computation span was defined as the maximum number of end 
digits recalled in serial order, with the added requirement that the corresponding 
arithmetic problems had been solved correctly.  
Consonant Updating: In this computer-based task, the participant was 
presented with a random sequence of between 6 and 12 consonants on a computer 
screen. Twenty-four such lists were presented, and in each case, the participant was 
unaware of the number of consonants to be presented. The task was always to recall 
the most recent six consonants in the order in which they were presented. The 
participant experienced six trials at each of the four list lengths: 6, 8, 10, and 12 items. 
The order in which the lists were presented was randomised. A single composite score 
of updating was calculated as in our previous paper[18].  
Chicago Word Fluency Test. Participants were instructed not to write any 
place names, peoples name or plurals in this test. Firstly participants were given five 
minutes to write down as many words as they could, beginning with the letter “S”. 
Secondly, they were given four minutes to write down as many four-letter words 
beginning with “C” as they could. Scores for both letter fluency tasks were the 
number of appropriate words in each case. The two fluency measures were 
standardised and averaged to form a single standardised composite measure of letter 
fluency. 
Using the present sample, our previous study[18] revealed that ecstasy/polydrug 
users were significantly impaired on these aspects of executive functioning, relative to 
a non ecstasy-using group which included both cannabis only and drug naive users. 
The present study has separated out cannabis only and drug naïve persons. On this 
basis, computation span scores were associated with a statistically significant overall 
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group difference, F(2,222) = 5.19, p<.01, with Dunnett’s t post hoc test revealing that 
the ecstasy/polydrug users performed significantly worse than cannabis only, p<.05, 
and drug naïve persons, p<.01. The consonant updating task was also associated with 
significant group effect, F(2,133) = 3.40, p<.05, with Dunnett’s t post hoc test 
revealing that the ecstasy/polydrug users performed significantly worse than cannabis 
only and drug naïve persons, p<.05 in both cases. Lastly the Chicago World Fluency 
test yielded a significant group difference, F(2,88) = 6.49, p<.01, with Dunnett’s t 
post hoc test revealing that the ecstasy/polydrug users performed significantly worse 
than cannabis only and drug naïve persons, p<.01 in both cases. 
 
Procedure 
Written informed consent was obtained from all participants. Ethical approval was 
obtained form the Ethics Committee of Liverpool John Moores University and the research 
was conducted in accordance with the ethical guidelines of the British Psychological Society. 
Participants completed the measures in a single session lasting between three to four hours
2
.  
Design 
Drug using group with three levels (drug naïve, cannabis only, and ecstasy/polydrug) 
served as the independent variable. Dependent variables were the various sleep measures 
together with the two measures of daytime sleepiness. 
 
RESULTS 
In all groups the majority of  participants indicated that they occasionally missed a 
night’s sleep however at 91% the proportion was significantly higher among ecstasy/polydrug 
users compared to cannabis-only (81%) and drug naïve (75%), χ2 (df=2; N=224) = 7.98, 
p<.05. In terms of the means and inter-quartile range, inspection of Table 2 reveals that 
ecstasy-polydrug users were more likely to describe themselves as ‘evening types’. Higher 
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scores on the sleep quality measure indicate poorer quality and on this basis drug naïve 
individuals appear to report better sleep quality compared to the other two groups.  
<<Insert Table 2 about here>> 
Since the data were ordinal in nature nonparametric tests were utilised. Inspection of 
Table 3 reveals that the group differences were statistically significant for the sleep type and 
approached significance for the sleep quality measure. Pairwise comparisons revealed that 
drug naïve individuals had significantly lower scores on the sleep type and sleep quality 
measures compared to ecstasy/polydrug users. Thus drug naïve persons were less likely to 
view themselves as evening types and believed that they had better sleep quality. Pairwise 
comparisons also revealed that cannabis-only users had significantly lower scores on the sleep 
type measure compared to ecstasy/polydrug users. Thus cannabis-only users were also less 
likely to view themselves as evening types.  
Looking at the proportion of participants describing themselves as definitely evening 
types, this was 11% among drug naïve persons which is similar to the proportion in the 
general population
[21]
. Among cannabis only users the proportion was 21%, while among 
ecstasy/polydrug users it was 37%. Definitely morning types were 4, 2, and 3% respectively 
for drug naïve, cannabis only, and ecstasy/polydrug compared with approximately 10% in the 
general population. 
<<Insert Table 3 about here>> 
No statistically significant group differences emerged on the remaining sleep 
measures. However, the pairwise difference between dug naïve and ecstasy/polydrug users on 
the Karolinska measure administered at the beginning of testing approached significance, 
p=.065 two tailed, as did the pairwise difference between cannabis only and ecstasy/polydrug 
users at the end of testing, p=.066 two tailed. Drug naïve individuals were less tired than 
ecstasy/polydrug at the beginning of testing while interestingly cannabis only users were 
more tired than ecstasy/polydrug at the end of testing. 
Inspection of Table 1 reveals that the standard deviation in relation to the periods of 
abstinence for cannabis and ecstasy was very large and there were substantial discrepancies 
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between the respective medians and means in relation to the time elapsed since last use.  Thus 
the groups contained participants who differed greatly in terms of the period of abstinence. It 
is possible that the drug-related effects on the different sleep measures may vary according to 
the length of abstinence and that the relationship may not be a monotonic one. With regard to 
ecstasy, in order to examine this possibility, participants were divided into different groups 
depending on their period of abstinence. Four such groups were formed, and these were 
selected so as to conform as closely as possible to the four quartiles constituting the 
distribution. Thus the four groups represented progressively increasing periods of abstinence. 
The first quartile comprised persons who had been abstinent for less than a week; the second 
more than one but less than three weeks; the third more than three but less than 12 weeks, and 
the fourth more than 12 weeks. These four groups were compared with cannabis only users 
and drug naïve persons on the measures of interest. The Kruskal Wallis test revealed that the 
overall group effect was nonsignificant for the two Karolinska measures, the Epworth 
Sleepiness Scale, morning tiredness, sleep quality and hours of sleep per night, with χ2 values 
(N=225, df=5) ranging between 0.80 and 8.07, p>.15 in all cases. The sleep type measure was 
associated with a statistically significant group difference, χ2 (N=225, df=5) = 16.70, p<.01. 
The trends across the groups are displayed in Figure 1.  Subsequent Mann-Whitney U 
analyses revealed that the first, third and fourth quartiles differed significantly from the drug 
naïve group, p<. .024, .016, and .001, respectively. The first, third and fourth quartiles also 
differed significantly from cannabis only users, p<. .042, .022, and .004, respectively. In all 
three cases ecstasy users were more likely to describe themselves as evening types compared 
to the cannabis only and drug naïve groups. Focussing on ecstasy users, the Jonckheere-
Terpstra Trend test failed to reveal a statistically significant trend with increasing duration of 
abstinence, J-T statistic = 0.877, p>.05. 
<<Insert Figure 1 about here>> 
While cannabis only users did not differ significantly from drug naïve persons on any 
of the measures, it is possible that such differences might emerge as periods of abstinence 
from cannabis vary. In order to examine this possibility, cannabis only users were divided 
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into four different groups (again based as closely as possible on quartiles) according to their 
period of abstinence. The first quartile comprised persons who had been abstinent for less 
than a week; the second more than one but less than four weeks; the third more than four but 
less than 20 weeks, and the fourth more than 20 weeks. Comparison of these four groups and 
drug naïve persons on the measures of interest yielded no statistically significant group 
differences on any of the sleep measures with χ2 values (N=106, df=5) ranging between 2.06 
and 7.10, p>.13 in all cases via the Kruskal Wallis test. 
In order to establish whether or not the cognitive deficits in ecstasy/polydrug users 
that were noted above were mediated by the significant group differences in sleep type, sleep 
quality and missing a night’s sleep, these three variables were included as covariates in the 
analyses of the cognitive measures with user group (drug naïve, cannabis-only, 
ecstasy/polydrug) again as the between participant independent variable. Following control 
for the sleep measures ecstasy/polydrug users continued to exhibit deficits on all of 
the cognitive measures: for computation span, F(2,216) = 5.73, p<.01, for consonant 
updating, F(2,127) = 4.44, p<.05, and for the Chicago World Fluency test F(2,83) = 
6.72, p<.01. 
  
DISCUSSION 
Among the measures included in the present study, only the sleep type indicator 
yielded an overall statistically significant group difference. In terms of the pairwise 
comparisons, on the sleep quality measure, drug naïve individuals achieved significantly 
lower scores compared with the ecstasy/polydrug group indicating that the drug naïve group 
judged their sleep quality to be better than the ecstasy/polydrug users. On the sleep type 
measure both drug naïve and cannabis only users were significantly less inclined to describe 
themselves as definitely evening types compared to ecstasy/polydrug users. All of these 
pairwise comparisons remained statistically significant at the Bonferroni corrected alpha level 
of .016. In relation to duration of abstinence, at unadjusted alpha levels, three of the four 
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quartiles contained significantly more individuals who were likely to describe themselves as 
evening types. The remaining quartile consisting of those who had been abstinent for one to 
three weeks, did not exhibit this tendency. However, with full Bonferroni correction (alpha = 
.006), only the group displaying the longest period of abstinence from ecstasy differed 
statistically from the cannabis only and drug naïve persons
3
. 
This difference in sleep type is particularly interesting. Over a third of 
ecstasy/polydrug users described themselves as definitely evening types, compared with just 
10% in the general population
[21]
 and 11% of drug naïve persons in the present study. In the 
animal literature, MDMA and other serotonin-related drugs such as fenfluramine have been 
shown to interfere with the body’s ability to “reset” its circadian clock in rats[22]. Although 
this decrement was slightly reduced at 20 weeks following administration, the deficits were 
still present, and the authors suggest that this is due to serotonergic degeneration caused by 
ecstasy and fenfluramine. This is further supported by Colbron et al
[23]
 who found that 
repeated exposure to MDMA in hamsters altered the ability of the circadian clock to phase 
shift. Thus it is possible that this difference in sleep type reflects a transient ecstasy-related 
shift in circadian rhythms in human ecstasy users. However, the proposition that ecstasy use 
causes individuals to become evening types must be treated with a degree of caution. It is 
equally possible that these individuals were evening types prior to the initiation of drug use. 
Future studies would do well to adopt longitudinal designs in which premorbid characteristics 
can be properly assessed. 
Statistically significant differences in self-reported sleep quality were also observed, 
with ecstasy/polydrug users reporting poorer sleep quality than drug naïve persons. This is in 
line with previous studies in ecstasy users where “restless sleep” has frequently been cited[3, 8, 
24, 25]
. 
On the Karolinska measure drug naïve individuals were less tired compared to 
ecstasy/polydrug users at the beginning of testing and cannabis users were more tired than 
ecstasy/polydrug users at the end of testing. However, even on a one-tailed basis, neither of 
these two differences was statistically significant following Bonferroni correction. In our 
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previous study
[18]
, ecstasy/polydrug users were found to differ significantly from the control 
group on the Karolinska measure at the beginning of testing. However, no significant 
difference was found in the present study despite the fact that the data were largely the same. 
In our previous study the control group contained cannabis only users, while in the present 
study these have been separated out as a distinct group. Furthermore, the present sample 
contained an additional 13 ecstasy/polydrug users and an additional 10 non-ecstasy users, 
recruited after the close of the previous study. The differences between the two studies 
highlight the potential importance of separating out different polydrug categories. 
While statistically significant group differences were observed on the sleep type, 
sleep quality and missing a night’s sleep measures, none of these appear to have mediated the 
significant ecstasy/polydrug -related group deficits that were observed on the cognitive 
measures which all remained significant following the inclusion of the relevant sleep 
measures as covariates. This would seem to suggest that the cognitive deficits do not arise 
from sleep deprivation, or restless sleep nor do they appear to reflect morningness-
eveningness differenceswhich might be associated with differential time of day effects in 
relation to testing. 
The fact that most of the sleep measures yielded no overall statistically significant 
group differences is surprising as it has been suggested that, in part, the cognitive deficits 
displayed by ecstasy users may reflect differences in lifestyle, for example Cole and 
Sumnall
[26]
 suggest that the lifestyle of an ecstasy user is one of constant circadian disruption, 
which has been responsible for similar cognitive deficits in aircrew (Chou et al. 2000 cited in 
Cole and Sumnall
[26]
). In the present study, if this were the case then one would expect that 
ecstasy users would report fewer average hours of sleep per night and greater subjective 
sleepiness. However, this was not the case. It is possible that the heterogeneous nature of the 
ecstasy/polydrug group might have been a factor in explaining the absence of sleep 
impairment. Interestingly Carhart-Harris et al
[1]
 did not observe significant sleep problems in 
their ecstasy/polydrug group. The sleep-related deficits that were observed in that study were 
limited to ecstasy-only users. Carhart-Harris et al have suggested that the sedative effects of 
 15 
cannabis might have counteracted the potential for sleep disturbance among the 
ecstasy/polydrug group and this may also have been the case in the present study. 
There were a number of limitations with the present study. Firstly, we had to rely on 
self-reports of previous drug use. While other ecstasy use studies have also relied on self-
report measures
[27, 28, 29, 30]
 clearly it would have been desirable to use objective testing 
methods (e.g. urine, hair). The data were accumulated over a period of years and while all 
participants completed a subset of measures, during the various phases of the project new 
cognitive measures were introduced and others were removed from the test battery. While all 
three groups experienced this changing pattern in equal measure, we cannot guarantee that the 
demands of the test procedure were equivalent in terms of their potential to give rise to 
fatigue over the entire duration of the project. Having said this, the length of the test session 
remained fairly constant throughout averaging between three and four hours with a break 
roughly half way through. 
To summarise, ecstasy/polydrug users and cannabis-only users and drug naïve 
persons performed similarly on most of the sleep measures. Most notable was the difference 
in sleep type between the ecstasy/polydrug users and the other two groups. Future research 
should seek to investigate this concept of a circadian shift in human users of the drug and also 
the apparent differences in morningness/eveningness as a construct
[31]
.  
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Figure Captions 
 
Figure 1: 
 
Sleep Type According to Period of Abstinence from Ecstasy From Most Recent (1st 
Quartile) to Most Abstinent (4th Quartile) Compared to Cannabis Only Users and 
Drug Naïve Persons. 
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Table 1. Age, Years of Education, Intelligence, and Measures of Illicit Drug Use for 
Cannabis-Only and Ecstasy/Polydrug users. 
 
 
 
 
Cannabis-Only Users Ecstasy/Polydrug Users 
 
 
Median Mean S.D. n Median Mean S.D. n 
Age 21 20.96 1.76 53 21 21.68 1.95 117 
Years of education 16 15.39 2.03 53 16 15.10 2.80 117 
Ravens Progressive Matrices 50 49.63 4.85 52 48 47.68 6.04 114 
Ecstasy         
Lifetime dose (tablets) - - - - 187 328.55 449.68 117 
Current use (tablets taken in 
previous 30 days) 
    1 3.09 4.84 116 
     Weeks since last use  
      
     3 23.30 52.84 117 
Cannabis         
Lifetime dose (joints) 76 631.26 1091.21 33 1052.5 3159.49 4597.49 87 
Current use (joints taken in 
previous 30 days) 
1 8.55 26.95 32 9.5 37.10 62.46 86 
     Weeks since last use  
      
4 31.51 70.25 52 0.57 24.46 76.82 97 
Cocaine         
Lifetime dose (grams)     22 53.29 88.47 47 
Current use (grams taken in 
previous 30 days) 
    1 1.39 1.88 45 
     Weeks since last use  
      
    3 14.20 36.67 91 
Amphetamine         
Lifetime dose (grams)     6 72.95 136.87 33 
Current use (grams taken in 
previous 30 days) 
    0 0.33 1.26 23 
     Weeks since last use  
      
    52 99.00 118.02 44 
 
 
 
Weeks since last use includes individuals who have used the drug in question on 
relatively few or on just a single occasion. Some individuals, especially infrequent 
users were unable to provide estimates for lifetime dose or current use. 
 
 
 
 22 
Table 2. Indicators of various sleep attributes and cognitive functions among drug naïve, cannabis-only and ecstasy/polydrug users 
 
 
 
Drug Naïve Cannabis Only Ecstasy/Polydrug 
 
 
Mean s.d Median 25Pctl 75Pctl Mean s.d Median 25Pctl 75Pctl Mean s.d Median 25Pctl 75Pctl 
Sleep Measures                
Sleep Type 
 
3.58 0.96 4 3 4 3.56 1.04 4 3 4 4.02 1.01 4 4 5 
Sleep Quality 
 
1.69 0.63 2 1 2 1.92 0.79 2 1 2 1.99 0.85 2 1 2.5 
Hours Sleep per 
Night 
8.06 1.07 8 8 9 8.02 1.33 8 7 9 7.97 1.47 8 7 9 
Morning State 
 
2.55 0.69 3 2 3 2.54 0.73 3 2 3 2.66 0.74 3 2 3 
Epworth 
Sleepiness Scale 
6.40 3.25 6 4 9 6.83 3.42 7 4 9 6.54 3.38 6 4 9 
Karolinska 
Sleepiness Scale 
         (beginning) 
4.26 1.36 4 3 5 4.74 1.63 5 3 6 4.85 1.57 5 3 6 
         (end) 5.50 1.64 6 4 7 6.01 1.42 6 5 7 5.49 1.53 6 4 7 
Cognitive Measures                
Computation 
Span 
4.59 1.58    4.42 1.32    3.84 1.68    
Letter Updating 4.15 0.65    4.18 0.63    3.83 0.81    
Chicago Word 
Fluency 
0.27 1.03    0.26 0.27    -0.40 0.84    
 
Sleep Type: 1 – definitely morning type; 2 – more morning; 3 – neither; 4 – more evening; 5 – definitely evening type. 
Sleep Quality: 1 – very well; 2 – satisfactory; 3 – not very well; 4 very badly. 
Morning Tiredness: 1 – very alert; 2 – fairly alert; 3 – fairly tired; 4 – very tired 
 
The Epworth and Karolinska Data and the cognitive measures were reported in our previous paper
[18]
.
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Table 3 
Inferential statistics corresponding to the drug use group effects and pairwise comparisons for the various sleep measures. 
 
 
 
Overall Effect Drug Naïve versus 
Cannabis Only 
Drug Naïve versus 
Ecstasy/Polydrug  
Cannabis Only versus 
Ecstasy/Polydrug 
 
 
χ2 (df=2; N=224) Mann-Whitney U Mann-Whitney U Mann-Whitney U 
Sleep Type 
 
13.45** 1381.00 2342.00** 2232.00** 
Sleep Quality 
 
4.78
†
 1210.00 2613.00* 2924.00 
Hours Sleep per 
Night 
 
0.48 1377.50 3020.50 2944.00 
Morning State 
 
1.00 1429.00 2987.00 2827.50 
Epworth 
Sleepiness Scale 
0.51 1367.00 3216.00 2794.00 
Karolinska 
Sleepiness Scale 
(beginning) 
3.26 
 
558.50 
 
1099.50
††† 
1542.50 
Karolinska 
Sleepiness Scale 
(end) 
3.43 551.00 1354.50 1259.50
††
 
 
 
** p<.01; * p<.05; ††† p = .065; †† p = .066; † p = .091, all two tailed. 
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1
 The Karolinska measure was not administered during the early stages of our research programme. Therefore the data that were reported correspond to 34 drug naïve, 39 
cannabis only and 82 ecstasy/polydrug users. 
2
 A small number of participants were unable to complete the test session due to other commitments. These individuals returned on a subsequent occasion to complete the test 
battery. 
3
 Full Bonferroni correction is only one means of controlling for inflated Type one error. It is worthy of note that the number of pairwise comparisons that might be expected 
to produce alpha values exceeding .05 purely by chance (the error rate per experiment) is less than one (8 × .05 = 0.4). Thus the fact that six of the eight comparisons were 
associated with alpha values less than .05 suggests that the sample as a whole is disproportionately characterised by evening types. 
 
 
 
 
 
 
